Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes

OncoImmunology

Volumn 5, Issue 2, 2016, Pages

  Cornwall, Scott M J ^a   Wikstrom, Matthew ^b   Musk, Arthur W ^c   Alvarez, John ^d   Nowak, Anna K ^c,e   Nelson, Delia J ^a  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d Mount Hospital   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Aging; CD40Ligand; immunotherapy; Mesothelioma; myeloid dendritic cells; plasmacytoid dendritic cells; survival outcomes

Indexed keywords

EID: 84959432152     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1082028     Document Type: Article

References (63)

1. B.W.Robinson, R.A.Lake. Advances in malignant mesothelioma. N Engl J Med 2005; 353:1591-603; PMID:16221782; http://dx.doi.org/10.1056/NEJMra050152
2. S.C.Kao, N.Pavlakis, R.Harvie, J.L.Vardy, M.J.Boyer, N.van Zandwijk, S.J.Clarke. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010; 16:5805-13; PMID:20956618; http://dx.doi.org/10.1158/1078-0432.CCR-10-2245
3. A.Linton, N.Pavlakis, R.O'Connell, M.Soeberg, S.Kao, S.Clarke, J.Vardy, N.van Zandwijk. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer 2014; 111:1860-9; PMID:25188323; http://dx.doi.org/10.1038/bjc.2014.478
4. C.Bianchi, L.Giarelli, G.Grandi, A.Brollo, L.Ramani, C.Zuch. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 1997; 6:162-6; PMID:9237066; http://dx.doi.org/10.1159/000343599
5. T.Fulop, A.Larbi, R.Kotb, G.Pawelec. Immunology of aging and cancer development. Interdiscip Top Gerontol 2013; 38:38-48; PMID:23503514; http://dx.doi.org/10.1159/000343599
6. C.Gravekamp, A.Jahangir. Is cancer vaccination feasible at older age? Exp Gerontol 2014; 54:138-44; PMID:24509231; http://dx.doi.org/10.1016/j.exger.2014.01.025
7. V.Izzi, L.Masuelli, I.Tresoldi, C.Foti, A.Modesti, R.Bei. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer Lett 2012; 322:18-34; PMID:22394996; http://dx.doi.org/10.1016/j.canlet.2012.02.034
8. C.Jackaman, S.Cornwall, A.M.Lew, Y.Zhan, B.W.Robinson, D.J.Nelson. Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells. Eur Respir J 2009; 34:162-75; PMID:19251786; http://dx.doi.org/10.1183/09031936.00101008
9. R.Hassan, A.C.Miller, E.Sharon, A.Thomas, J.C.Reynolds, A.Ling, R.J.Kreitman, M.M.Miettinen, S.M.Steinberg, D.H.Fowler Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 2013; 5:208ra147; PMID:24154601; http://dx.doi.org/10.1126/scitranslmed.3006941
10. L.Calabro, A.Morra, E.Fonsatti, O.Cutaia, C.Fazio, D.Annesi, M.Lenoci, G.Amato, R.Danielli, M.Altomonte Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 2015; 3(4):301-9; PMID:25819643; http://dx.doi.org/10.1016/S2213-2600(15)00092-2
11. J.Banchereau, F.Briere, C.Caux, J.Davoust, S.Lebecque, Y.J.Liu, B.Pulendran, K.Palucka. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811; PMID:10837075; http://dx.doi.org/10.1146/annurev.immunol.18.1.767
12. C.Caux, B.Vanbervliet, C.Massacrier, C.Dezutter-Dambuyant, B.de Saint-Vis, C.Jacquet, K.Yoneda, S.Imamura, D.Schmitt, J.Banchereau. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF α. J Exp Med 1996; 184:695-706; PMID:8760823; http://dx.doi.org/10.1084/jem.184.2.695
13. M.C.Rissoan, V.Soumelis, N.Kadowaki, G.Grouard, F.Briere, R.de Waal Malefyt, Y.J.Liu. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283:1183-6; PMID:10024247; http://dx.doi.org/10.1126/science.283.5405.1183
14. S.H.Robbins, T.Walzer, D.Dembele, C.Thibault, A.Defays, G.Bessou, H.Xu, E.Vivier, M.Sellars, P.Pierre Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol 2008; 9:R17; PMID:18218067; http://dx.doi.org/10.1186/gb-2008-9-1-r17
15. B.Blom, S.Ho, S.Antonenko, Y.J.Liu. Generation of interferon α-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J Exp Med 2000; 192:1785-96; PMID:11120775; http://dx.doi.org/10.1084/jem.192.12.1785
16. G.Grouard, M.C.Rissoan, L.Filgueira, I.Durand, J.Banchereau, Y.J.Liu. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997; 185:1101-11; PMID:9091583; http://dx.doi.org/10.1084/jem.185.6.1101
17. V.Soumelis, Y.J.Liu. From plasmacytoid to dendritic cell: morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur J Immunol 2006; 36:2286-92; PMID:16892183; http://dx.doi.org/10.1002/eji.200636026
18. D.N.Hart. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90:3245-87; PMID:9345009
19. T.K.Hoffmann, J.Muller-Berghaus, R.L.Ferris, J.T.Johnson, W.J.Storkus, T.L.Whiteside. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 2002; 8:1787-93; PMID:12060618
20. X.J.Ma, X.L.Pan, Z.H.Lv, F.L.Xu, Y.Liu da, P.Lei da, M.Xia, X.Y.Luan. Therapeutic influence on circulating and monocyte-derived dendritic cells in laryngeal squamous cell carcinoma patients. Acta Otolaryngol 2009; 129:84-91; PMID:18607895; http://dx.doi.org/10.1080/00016480802020459
21. K.Sakakura, K.Chikamatsu, K.Takahashi, T.L.Whiteside, N.Furuya. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2006; 55:151-9; PMID:15889251; http://dx.doi.org/10.1007/s00262-005-0697-y
22. A.Sciarra, M.Lichtner, G.A.Autran, C.Mastroianni, R.Rossi, F.Mengoni, C.Cristini, A.Gentilucci, V.Vullo, F.Di Silverio. Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate 2007; 67:1-7; PMID:17075798; http://dx.doi.org/10.1002/pros.20431
23. S.Della Bella, S.Nicola, L.Brambilla, A.Riva, S.Ferrucci, P.Presicce, V.Boneschi, E.Berti, M.L.Villa. Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma. Clin Immunol 2006; 119:317-29; PMID:16527545; http://dx.doi.org/10.1016/j.clim.2006.01.011
24. S.J.Harrison, I.M.Franklin, J.D.Campbell. Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy. Leuk Lymphoma 2008; 49:2272-83; PMID:19052974; http://dx.doi.org/10.1080/10428190802464729
25. A.Pinzon-Charry, C.S.Ho, T.Maxwell, M.A.McGuckin, C.Schmidt, C.Furnival, C.M.Pyke, J.A.López. Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br J Cancer 2007; 97:1251-9; PMID:17923873; http://dx.doi.org/10.1038/sj.bjc.6604018
26. V.Tjomsland, P.Sandstrom, A.Spangeus, D.Messmer, J.Emilsson, U.Falkmer, S.Falkmer, K.E.Magnusson, K.Borch, M.Larsson. Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity? BMC Cancer 2010; 10:87; PMID:20214814; http://dx.doi.org/10.1186/1471-2407-10-87
27. A.Troy, P.Davidson, C.Atkinson, D.Hart. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol 1998; 160:214-9; PMID:9628653; http://dx.doi.org/10.1016/S0022-5347(01)63093-3
28. T.Ninomiya, S.M.Akbar, T.Masumoto, N.Horiike, M.Onji. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 1999; 31:323-31; PMID:10453947; http://dx.doi.org/10.1016/S0168-8278(99)80231-1
29. C.Jackaman, C.S.Bundell, B.F.Kinnear, A.M.Smith, P.Filion, D.van Hagen, B.W.Robinson, D.J.Nelson. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 2003; 171:5051-63; PMID:14607902; http://dx.doi.org/10.4049/jimmunol.171.10.5051
30. M.Cernadas, J.Lu, G.Watts, M.B.Brenner. CD1a expression defines an interleukin-12 producing population of human dendritic cells. Clin Exp Immunol 2009; 155:523-33; PMID:19220838; http://dx.doi.org/10.1111/j.1365-2249.2008.03853.x
31. Z.Zeng, X.Xu, Y.Zhang, J.Xing, J.Long, L.Gu, X.Wang, D.Sun, W.Ka, W.Yao Tumor-derived factors impaired motility and immune functions of dendritic cells through derangement of biophysical characteristics and reorganization of cytoskeleton. Cell Motil Cytoskeleton 2007; 64:186-98; PMID:17183544; http://dx.doi.org/10.1002/cm.20175
32. K.Imai, Y.Minamiya, S.Koyota, M.Ito, H.Saito, Y.Sato, S.Motoyama, T.Sugiyama, J.Ogawa. Inhibition of dendritic cell migration by transforming growth factor-beta1 increases tumor-draining lymph node metastasis. J Exp Clin Cancer Res 2012; 31:3; http://dx.doi.org/10.1186/1756-9966-31-3
33. C.Esche, A.Gambotto, Y.Satoh, V.Gerein, P.D.Robbins, S.C.Watkins, M.T.Lotze, M.R.Shurin. CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur J Immunol 1999; 29:2148-55; PMID:10427977; http://dx.doi.org/10.1002/(SICI)1521-4141(199907)29:07%3c2148::AID-IMMU2148%3e3.0.CO;2-F
34. P.DeLong, R.G.Carroll, A.C.Henry, T.Tanaka, S.Ahmad, M.S.Leibowitz, D.H.Sterman, C.H.June, S.M.Albelda, R.H.Vonderheide. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 2005; 4:342-6; PMID:15846066; http://dx.doi.org/10.4161/cbt.4.3.1644
35. O.Murillo, J.Dubrot, A.Palazon, A.Arina, A.Azpilikueta, C.Alfaro, S.Solano, M.C.Ochoa, C.Berasain, I.Gabari In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol 2009; 39:2424-36; PMID:19662633; http://dx.doi.org/10.1002/eji.200838958
36. H.van Cruijsen, A.A.van der Veldt, L.Vroling, D.Oosterhoff, H.J.Broxterman, R.J.Scheper, G.Giaccone, J.B.Haanen, A.J.van den Eertwegh, E.Boven Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008; 14:5884-92; PMID:18794101; http://dx.doi.org/10.1158/1078-0432.CCR-08-0656
37. C.Jackaman, S.Cornwall, P.T.Graham, D.J.Nelson. CD40-activated B cells contribute to mesothelioma tumor regression. Immunol Cell Biol 2011; 89:255-67; PMID:20628372; http://dx.doi.org/10.1038/icb.2010.88
38. C.Jackaman, A.M.Lew, Y.Zhan, J.E.Allan, B.Koloska, P.T.Graham, B.W.Robinson, D.J.Nelson. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 2008; 20:1467-79; PMID:18824504; http://dx.doi.org/10.1093/intimm/dxn104
39. C.Jackaman, S.Lansley, J.E.Allan, B.W.Robinson, D.J.Nelson. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase. Int Immunol 2012; 24:357-68; PMID:22354912; http://dx.doi.org/10.1093/intimm/dxs005
40. S.A.Broomfield, R.G.van der Most, A.C.Prosser, S.Mahendran, M.G.Tovey, M.J.Smyth, B.W.Robinson, A.J.Currie. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol 2009; 182:5217-24; PMID:19380767; http://dx.doi.org/10.4049/jimmunol.0803826
41. A.M.McDonnell, W.J.Lesterhuis, A.Khong, A.K.Nowak, R.A.Lake, A.J.Currie, B.W.Robinson. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol 2015; 45:49-59; PMID:25316312; http://dx.doi.org/10.1002/eji.201444722
42. W.J.Lesterhuis, J.Salmons, A.K.Nowak, E.N.Rozali, A.Khong, I.M.Dick, J.A.Harken, B.W.Robinson, R.A.Lake. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PloS one 2013; 8:e61895; PMID:23626745; http://dx.doi.org/10.1371/journal.pone.0061895
43. A.K.Nowak, B.W.Robinson, R.A.Lake. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63:4490-6; PMID:12907622
44. S.Broomfield, A.Currie, R.G.van der Most, M.Brown, I.van Bruggen, B.W.Robinson, R.A.Lake. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 2005; 65:7580-4; PMID:16140921; http://dx.doi.org/10.1158/0008-5472.CAN-05-0328
45. A.Khong, A.L.Cleaver, M.Fahmi Alatas, B.C.Wylie, T.Connor, S.A.Fisher, S.Broomfield, W.J.Lesterhuis, A.J.Currie, R.A.Lake The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40. BMC Cancer 2014; 14:969; PMID:25518732; http://dx.doi.org/10.1186/1471-2407-14-969
46. E.W.Alley, L.R.Molife, A.Santoro, K.Beckey, S.Yuan, J.D.Cheng, B.Piperdi, J.H.M.Schellens. Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028 American Association for Cancer Research conference abstract number CT103 2015
47. P.A.Stumbles, R.Himbeck, J.A.Frelinger, E.J.Collins, R.A.Lake, B.W.Robinson. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 2004; 173:5923-8; PMID:15528325; http://dx.doi.org/10.4049/jimmunol.173.10.5923
48. B.Homet Moreno, G.Parisi, L.Robert, A.Ribas. Anti-PD-1 Therapy in Melanoma. Semin Oncol 2015; 42:466-73; PMID:25965365; http://dx.doi.org/10.1053/j.seminoncol.2015.02.008
49. A.M.Di Giacomo, R.Danielli, M.Guidoboni, L.Calabro, D.Carlucci, C.Miracco, L.Volterrani, M.A.Mazzei, M.Biagioli, M.Altomonte Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009; 58:1297-306; PMID:19139884; http://dx.doi.org/10.1007/s00262-008-0642-y
50. P.A.Ott, F.S.Hodi, C.Robert. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19:5300-9; PMID:24089443; http://dx.doi.org/10.1158/1078-0432.CCR-13-0143
51. E.S.Cannizzo, C.C.Clement, K.Morozova, R.Valdor, S.Kaushik, L.N.Almeida, C.Follo, R.Sahu, A.M.Cuervo, F.Macian Age-related oxidative stress compromises endosomal proteostasis. Cell Rep 2012; 2:136-49; PMID:22840404; http://dx.doi.org/10.1016/j.celrep.2012.06.005
52. T.L.Whiteside, J.Stanson, M.R.Shurin, S.Ferrone. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 2004; 173:1526-34; PMID:15265880; http://dx.doi.org/10.4049/jimmunol.173.3.1526
53. H.Onishi, T.Morisaki, E.Baba, H.Kuga, H.Kuroki, K.Matsumoto, M.Tanaka, M.Katano. Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. Clin Immunol 2002; 105:286-95; PMID:12498810; http://dx.doi.org/10.1006/clim.2002.5293
54. D.I.Gabrilovich, J.Corak, I.F.Ciernik, D.Kavanaugh, D.P.Carbone. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997; 3:483-90; PMID:9815709.
55. K.Shortman, Y.J.Liu. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2:151-61; PMID:11913066; http://dx.doi.org/10.1038/nri746
56. I.Fricke, N.Mirza, J.Dupont, C.Lockhart, A.Jackson, J.H.Lee, J.A.Sosman, D.I.Gabrilovich. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007; 13:4840-8; PMID:17699863; http://dx.doi.org/10.1158/1078-0432.CCR-07-0409
57. J.Helft, J.Bottcher, P.Chakravarty, S.Zelenay, J.Huotari, B.U.Schraml, D.Goubau, C.Reis E Sousa. GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. Immunity 2015; 42:1197-211; PMID:26084029; http://dx.doi.org/10.1016/j.immuni.2015.05.018
58. D.H.Sterman, A.Recio, R.G.Carroll, C.T.Gillespie, A.Haas, A.Vachani, V.Kapoor, J.Sun, R.Hodinka, J.L.Brown A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007; 13:4456-66; PMID:17671130; http://dx.doi.org/10.1158/1078-0432.CCR-07-0403
59. A.Khong, D.J.Nelson, A.K.Nowak, R.A.Lake, B.W.Robinson. The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol 2012; 31:246-66; PMID:22804570; http://dx.doi.org/10.3109/08830185.2012.698338
60. C.S.Lages, I.Lewkowich, A.Sproles, M.Wills-Karp, C.Chougnet. Partial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/ PD-L1 pathway. Aging cell 2010; 9:785-98; PMID:20653631; http://dx.doi.org/10.1111/j.1474-9726.2010.00611.x
61. L.Calabro, A.Morra, E.Fonsatti, O.Cutaia, G.Amato, D.Giannarelli, A.M.Di Giacomo, R.Danielli, M.Altomonte, L.Mutti Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013; 14:1104-11; PMID:24035405; http://dx.doi.org/10.1016/S1470-2045(13)70381-4
62. N.Romani, S.Gruner, D.Brang, E.Kampgen, A.Lenz, B.Trockenbacher, G.Konwalinka, P.O.Fritsch, R.M.Steinman, G.Schuler. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93; PMID:8006603; http://dx.doi.org/10.1084/jem.180.1.83
63. D.Nelson, C.Bundell, B.Robinson. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes. J Immunol 2000; 165:6123-32; PMID:11086045; http://dx.doi.org/10.4049/jimmunol.165.11.6123